Securities code: 603590 securities abbreviation: Beijing Konruns Pharmaceutical Co.Ltd(603590) Announcement No.: pro 2022-003 Beijing Konruns Pharmaceutical Co.Ltd(603590)
Announcement on the implementation results of phase II share repurchase and share change
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1、 Repurchase approval and repurchase plan content
Beijing Konruns Pharmaceutical Co.Ltd(603590) (hereinafter referred to as “the company”) held the 14th meeting of the third board of directors and the 12th meeting of the third board of supervisors on January 20, 2021, deliberated and adopted the proposal on the second phase of repurchase of shares of the company by centralized bidding transaction and other proposals, On January 26, 2021, Beijing Konruns Pharmaceutical Co.Ltd(603590) repurchase report on the second phase of repurchase of company shares by centralized bidding transaction (Announcement No.: p.2021-011) was disclosed. The main contents of the share repurchase plan are as follows:
The company will use its own funds to buy back the company’s shares in the form of centralized bidding transaction, and all the repurchased shares will be used for employee stock ownership plan or equity incentive. The total repurchase fund shall not be less than 60 million yuan (inclusive) and not more than 120 million yuan (inclusive), the repurchase price shall not exceed 45 yuan / share (inclusive), and the repurchase period shall be within 12 months from the date when the company’s board of directors deliberates and approves the share repurchase plan.
2、 Implementation of repurchase
(I) on January 27, 2021, the company implemented the second phase of share repurchase for the first time, and disclosed the situation of share repurchase for the first time on January 28, 2021. For details, see the announcement on Beijing Konruns Pharmaceutical Co.Ltd(603590) initial repurchase of company shares by centralized bidding transaction (Announcement No.: Pro 2021-013) disclosed by the company on the designated information disclosure media.
(II) as of January 19, 2022, the company has completed the second phase of share repurchase. The company has actually repurchased 2273523 shares of the company through centralized bidding transaction, accounting for 1.42% of the total share capital of the company. The highest repurchase price is 37.87 yuan / share, the lowest repurchase price is 31.46 yuan / share, the average repurchase price is 34.88 yuan / share, and the total amount of funds used is 79308517.19 yuan (excluding transaction costs). The share repurchase plan has been implemented.
(III) in the process of share repurchase, the company strictly abides by the provisions of relevant laws and regulations and purchases shares
Legal and compliant, the actual implementation of the repurchase plan is not different from the original disclosed repurchase plan, and the company has completed the repurchase according to the disclosed plan.
(IV) impact of the implementation of the share repurchase plan on the company
The company’s share repurchase will continue to be used for the implementation of the company’s employee stock ownership plan or equity incentive, which is conducive to improving the cohesion of employees and the competitiveness of the company, realizing the consistency of the interests of shareholders, the company and employees, fully promoting the realization of the company’s strategic objectives and improving the overall value of the company.
The implementation of the share repurchase plan will not have a significant impact on the company’s business activities, financial status, R & D and future development, cause the company’s equity distribution not to meet the listing conditions, and cause changes in the company’s control.
3、 Shares bought and sold by relevant entities during the repurchase period
On January 21, 2021, the company disclosed the repurchase of shares for the first time. For details, please refer to the announcement on the second phase of repurchase of shares of the company by means of centralized bidding transaction (Announcement No.: p.2021-006) disclosed by the company in the designated information disclosure media. From the date when the company first disclosed the repurchase of shares to the trading day before the disclosure of this announcement, through the internal self-examination of the company, the directors, supervisors, senior managers, controlling shareholders, actual controllers and concerted actions of the company did not buy or sell the company’s shares.
4、 Changes in shares repurchased this time
Before and after the share repurchase, the changes of the company’s shares are as follows:
Before and after this repurchase
Share class share number proportion share number proportion (share) (%) (share) (%)
1、 Limited shares 76632360 47.90 0.00 (Note 1)
2、 Unlimited shares 83367640 52.10 160000000 100.00
Including: 1235100.77 3508623.19 special securities account for share repurchase of the company (Note 2)
Total number of shares 1600000000 100.00 1600000000 100.00
Note 1: 76632360 restricted shares before this repurchase were lifted in August 2021. For details, see the company’s announcement Lin 2021-089 disclosed in the designated information disclosure media on August 24, 2021.
Note 2: before this repurchase, the company has implemented the first phase of repurchase, and has actually repurchased 3230000 shares of the company through centralized bidding transaction, accounting for 2.02% of the total share capital of the company, of which 1994900 shares have been used in the employee stock ownership plan, and the remaining 1235100 shares have been repurchased in the first phase, which are currently deposited in the special account for repurchase of the company
For details, please refer to the announcement Lin 2021-003 disclosed by the company on the designated information disclosure media on January 16, 2021.
5、 Disposal arrangements for repurchased shares
2273523 shares were repurchased by the company this time. At present, all of them are deposited in the special securities account for repurchase opened by the company. As of January 19, 2022, the number of shares in the special securities account for repurchase by the company was 3508623 (including 1235100 remaining shares repurchased in the first phase). According to the company’s share repurchase plan, all the shares repurchased by the company will be used for employee stock ownership plan or equity incentive. The company shall complete the transfer of the repurchased shares within three years after the disclosure of the announcement of the repurchase results, and the unused shares will be cancelled according to law.
The subsequent company will use the repurchased shares according to the purpose of disclosure, and perform the decision-making procedures and information disclosure obligations as required.
It is hereby announced.
Beijing Konruns Pharmaceutical Co.Ltd(603590) board of directors January 20, 2022
